Blog

When to conduct hepatic impairment studies and when modeling may be enough

How to decide if a hepatic impairment study is required, choose the right study design,…

Zoe BarterJuly 13, 2026

Conference

ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop

Matt Zierhut, PhD MBAJuly 9, 2026

Blog

Dosimetry for radiopharmaceutical therapy: From measurement to dose justification

Why dosimetry for radiopharmaceutical therapy needs more than absorbed dose. How BED, radiation dosimetry &…

Hunter Stephens, PhDJuly 7, 2026

On-Demand Webinar

The Power of Modeling: Speed, Early De-Risking, and Regulatory Success for Forward-Thinking Sponsors

Learn how PBPK and QSP modeling support faster drug development by enabling smarter dose selection,…

CertaraJuly 1, 2026

Blog

Enhancing clinical trials with real-world evidence in pregnancy research

Learn how real-world evidence improves clinical trials in pregnancy by enhancing safety data, trial design,…

Alekhya Lavu, PhD, PharmDJune 26, 2026

Announcement

Certara Launches Bio Venture Catalyst for Emerging Biotechs to De-risk Investment and Accelerate Development

Integrated offering combines drug development, regulatory, commercial, and investor strategy expertise to help early-stage biotech…

Danielle PillsburyJune 23, 2026

Poster

Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies

Discover how endogenous ligand competition was incorporated into a whole-body PBPK model to improve prediction…

CertaraJune 23, 2026

Poster

Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study

Learn how Certara's IO Simulator was used to predict efficacy, cytokine release syndrome risk, and…

CertaraJune 23, 2026

Poster

Machine Learning-Based Covariate Selection for Population Pharmacokinetic Modeling

Authors: Ibtissem Rebai (Certara), Stephen Duffull (Certara), Ayman Akil (Certara), Anna Largajolli (Certara), Floris Fauchet…

CertaraJune 22, 2026

Poster

Shaping the future of AI/ML in pharmacometrics through collaboration, education and best practices

Discover how the AI/ML Special Interest Group is advancing responsible artificial intelligence in pharmacometrics through…

CertaraJune 22, 2026

Drug Development

When to conduct hepatic impairment studies and when modeling may be enough

ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop

Dosimetry for radiopharmaceutical therapy: From measurement to dose justification

The Power of Modeling: Speed, Early De-Risking, and Regulatory Success for Forward-Thinking Sponsors

Enhancing clinical trials with real-world evidence in pregnancy research

Certara Launches Bio Venture Catalyst for Emerging Biotechs to De-risk Investment and Accelerate Development

Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies

Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study

Machine Learning-Based Covariate Selection for Population Pharmacokinetic Modeling

Shaping the future of AI/ML in pharmacometrics through collaboration, education and best practices

Newsletter sign up

Quick links

Solutions

Contact